Nederlandse Coöperatieve Studie naar de Adequaatheid van Dialyse

Necosad Study Group Papers


  1. Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after start of treatment. Am J Kidney Dis 1997;29:584-592

  2. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT for the NECOSAD Study Group. Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999;56:720-728

  3. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT for the NECOSAD Study Group. Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). Nephrol Dial Transplant 1999;14:1163-1170

  4. Jager KJ, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JGP, Stevens P, Bos WJW, Krediet RT, for the NECOSAD Study group. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int 1999;55:1476-1485

  5. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Stevens P, Krediet RT, for the NECOSAD Study Group. Dialysis in the Netherlands: the clinical condition of new patients put into a European perspective. Nephrol Dial Transplant 1999;14:2438-2444

  6. Korevaar JC, Jansen MAM, Dekker FW, Boeschoten EW, Krediet RT for the NECOSAD Study Group. Estimation of residual GFR and renal Kt/V-urea from creatinine clearance in End-stage renal disease patients. Adv Perit Dial 1999;15:132-137

  7. Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. Adv Perit Dial 1999;15:222-225

  8. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT for the NECOSAD Study Group. Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). Am J Kidney Dis 2000;35:69-79

  9. Merkus MP, Krediet RT. Quality of life and functional status in chronic hemo- and peritoneal dialysis. In: Complications of dialysis - Recognition and Management. Lameire NH, Mehta RL (eds). New York, Marcel Dekker Inc 2000:497-515

  10. Korevaar JC, Jansen MAM, Merkus MP, Dekker FW, Boeschoten EW, Krediet RT. Quality of life in predialysis ESRD patients at the initiation of dialysis therapy. Perit Dial Int 2000;20:69-75

  11. Jansen MAM, Korevaar JC, Dekker FW, Boeschoten EW, Stevens P, Krediet RT and the NECOSAD Study Group. Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 2001;12:157-163

  12. Jager KJ, Merkus MP, Huisman RM, Boeschoten EW, Dekker FW, Korevaar JC, Tijssen JGP, Krediet RT. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001;12:1272-1279

  13. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Tijssen JGP, Krediet RT. What happens to patients starting dialysis in the Netherlands? Neth J Med 2001;58:163-173

  14. Wit de GA, Polder JJ, Jager KJ, de Charro FTh. De maatschappelijke kosten van nierziekten in Nederland. Tijdschrift voor Gezondheidswetenschappen 2001;79:49-54

  15. Korevaar JC, Jansen MAM, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, Bossuyt PMM. When to initiate dialyses - effect of proposed US guideline on survival. The Lancet 2001;358:1046-1051

  16. Wit de GA, Merkus MP, Krediet RT, Charro de F Th. A comparison of quality of life of patients on automated and continuous ambulatory peritoneal dialysis. Perit Dial Int 2001;21:306-31

  17. Manen van JG, Korevaar JC, Dekker FW, Reuselaars MC, Boeschoten EW, Krediet RT. Changes in Employment status in end-stage renal disease patients during the first year of dialysis. Perit Dial Int 2001;21:595-601

  18. Jansen MAM, Korevaar JC, Dekker FW, Boeschoten EW, Stevens P, Krediet RT and the NECOSAD Study Group. Relationship between Kt/Vurea and nPNA in predialysis patients and in chronic PD patients without residual renal function. Perit Dial Int 2001;21:509-515

  19. Manen van JG, Korevaar JC, Dekker FW, Boeschoten EW, PMM Bossuyt, Krediet RT for the NECOSAD Study Group. How to adjust for comorbidity in survival studies in End-stage Renal Disease patients: a comparison of different indices. Am J Kidney Dis 2002;40:82-89

  20. Jansen MAM, Hart AAM, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the decline rate of residual renal function in incident dialysis patients. Kidney Int 2002;62:1046-1053

  21. Korevaar JC, Jansen MAM, Dekker FW, Boeschoten EW, Bossuyt PMM, Krediet RT. Early start of dialysis treatment is not associated with better health-related quality of life - Evaluation of a DOQI guideline. Am J Kidney Dis 2002;39:108-115

  22. Korevaar JC, Merkus MP, Jansen MAM, Dekker FW, Boeschoten EW, Krediet RT. Validation of the KDQOL-SFTM : a dialysis targeted health measure. Qual Life Res 2002;11:437-447

  23. Termorshuizen F, Korevaar J.C, Dekker F.W, Jager K.J, van Manen J.G, Boeschoten E.W, Krediet R.T, for the NECOSAD Study Group. Time trends in initiation and dose of dialysis in end-stage renal disease patients in the Netherlands. Nephrol Dial Transplant 2003;18:552-558

  24. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT, for the NECOSAD Study Group. The relative importance of residual renal function compared to peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (Necosad)-2. Am J Kidney Dis 2003;41:1293 1302

  25. Manen van JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PMM, Krediet RT, for the NECOSAD Study Group. Adjustment for Comorbitity in Studies on Health Status in ESRD Patients: Which Comorbidity Index to Use? J Am Soc Nephrol 2003;14:478-485

  26. Lindhorst GE, Hollak CEM, Korevaar JC, Manan van JG, Aerts JMFG, Boeschoten EW. Alpha galactosidase deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584

  27. Korevaar JC, Dekker FW, Krediet RT. Initiation of dialysis - Is the problem solved by NECOSAD? Nephrol Dial Transplant 2003;18:1228-1236

  28. Korevaar JC, Manen van J.G, Boeschoten E.W, Dekker F.W, Krediet R.T, for the NECOSAD Study Group. Evaluation of Guidelines for Peritoneal Dialysis Patients: A Review from the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Peritoneal Dial Today Contrib Nephrol. Basel, Karger 2003;140:142-150

  29. Groothof JW, Grootenhuis MA, Offringa M, Gruppen MP, Korevaar JC, Heymans HAS. Quality of life in adults with end-stage renal disease since childhood is only partially impaired Nephrol Dial Transplant 2003;18:310-317

  30. Termorshuizen F, Korevaar JC, Dekker FW, Manen van JG, Boeschoten EW, Krediet RT, for the NECOSAD Study Group. Hemodialysis and Peritoneal Dialysis: Comparison of Adjusted Mortality Rates According to the Duration of Dialysis: Analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:2851-2860

  31. Korevaar JC, Feith GW, Dekker FW, Manen van JG, Boeschoten EW, Bossuyt PMM, Krediet RT for the NECOSAD Study Group. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: A randomised controlled trial. Kidney Int 2003;64:2222-2228

  32. Termorshuizen F, Dekker FW, Manen van JG, Korevaar JC, Boeschoten EW, Krediet RT for the NECOSAD Study Group. Relative Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialysis Patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-1070

  33. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW for the NECOSD Study Group. The Effect of Contraindications and Patient Preference on Dialysis Modality Selection in ESRD Patients in The Netherlands. Am J Kidney Dis 2004;43:891-899

  34. Korevaar JC, Manen van JG, Dekker FW, Waart de DR, Boeschoten EW, and Krediet RT for the NECOSAD Study Group. Effect of an Increase in C-Reactive Protein Level during a Hemodialysis Session on Mortality. J Am Soc Nephrol 2004;15:2916-2922

  35. Korevaar JC, Manen van JG, Dekker FW, Boeschoten EW, Krediet RT for the NECOSAD Study Group. When to start dialysis, where do we stand? PDI 2005;25,S3:S69-S72

  36. Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, Boeschoten EW, Krediet RT, Daha MR, Dekker FW, for the NECOSAD Study Group. Incidence of rhu-epoietin hyporesponse, epo associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005;68:1215-1222

  37. Jansen MAM, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT, for the NECOSAD Study Group. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005; 68:1199-1205

  38. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT for the NECOSAD Study Group.The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association With Mortality in Dialysis Patients. Am J of Kidney Dis 2005;46:925-932

  39. Sman-de Beer van der F, Verhagen C, Rombach SM, Boorsma P, Manen van JG, Korevaar JC, Bogaard van den R, Boeschoten EW, Krediet RT, Navis GJ, Broucke van den JP, Dekker FW, for the NECOSAD Study Group. Angiotensin-convering enzyme gene insertion/deletion polymorphism is associated with mortality in a prospective study of patients starting with dialysis. Kidney Int 2005;68:2237-2243

  40. Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, for the NECOSAD Study Group. What have we learned from NECOSAD; Practical implications for PD patients. Perit Dial Int; in press

  41. Havekes B, Manen van JG, Krediet RT, Boeschoten EW, Vandenbroucke JP, Dekker FW, for the NECOSAD Study Group. Serum Troponin T Concentrationas a Predictor of Mortality in Hemodialysis and Peritoneal Dialysis Patients. Am J Kidney Dis 2006;47:823-829

  42. Rutten JHW, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, Boomsma F, Meiracker AH for the NECOSAD Study Group. BNP en ANP predict survival in peritoneal dialysis. PDI; in press

  43. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, and Raymond T. Krediet. Hyperphoshateamia and Related Mortality. Nephrol Dial transplant May 2006

  44. Noordzij M, Korevaar JC, Bos WJ, Boeschoten EW, Dekker FW, Bossuyt PM, Krediet RT for the NECOSAD Study Group. Mineral metabolism and cardiovascular morbidity and mortality risk- peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant June 2006

  45. Elzen den WPJ, Manen van JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006;1588-1595

  46. Rutten JH, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, Boomsma F, van den Meiracker AH. B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. Perit Dial Int 26 (5):598-602, 2006.

  47. Noordzij M, Boeschoten EW, Bos WJ, Dekker FW, Bossuyt PM, Krediet RT, Korevaar JC for the NECOSAD Study Group. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol Dial Transplant, 2007.

  48. Hermans MMH, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KML, Krediet RT, Dekker FW, for The Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 72 (2):202-207, 2007.

  49. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 22 (6):1633-1638, 2007.

  50. Krediet RT, Boeschoten EW, Dekker FW. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial 20 (3):205-208, 2007.

  51. Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT. What have we learned from NECOSAD? Practical implications for peritoneal dialysis patients. Perit Dial Int 27 (1):11-15, 2007.

  52. Mutsert de R, Snijder MB, van der Sman-de Beer F, Seidell JC, Boeschoten EW, Krediet RT, Dekker JM, Vandenbroucke JP, Dekker FW. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 18 (3):967-974, 2007.

  53. Thong MS, Kaptein AA, Krediet RT, Boeschoten EW, Dekker FW. Social support predicts survival in dialysis patients. Nephrol Dial Transplant 22 (3):845-850, 2007.

  54. van Manen JG, van Dijk PC, Stel VS, Dekker FW, Cleries M, Conte F, Feest T, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 22 (1):187-195, 2007.

  55. Grootendorst DC, Jager DJ de, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW, and the NECOSAD Study Group. Excellent agreement between c-reactive protein measurement methods in end stage renal disease patients: no additional power for mortality prediction with high-sensitivity CRP. NDT 2007; 22: 3277-3284.

  56. Thong MS, Kaptein AA, Benyamini Y, Krediet RT, Boeschoten EW, Dekker FW; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. Association between a self-rated health question and mortality in young and old dialysis patients: a cohort study. Am J Kidney Dis. 2008 Jul;52(1):111-7.

  57. Mutsert RD, Grootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW; the NECOSAD Study Group. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008 Apr 9.

  58. Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB; NECOSAD study group. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline. Blood Purif. 2008;26(3):231-7.

  59. Kreutz R, Bolbrinker J, van der Sman-de Beer F, Boeschoten EW, Dekker FW, Kain S, Martus P, Sietmann A, Friedrichs F, Stoll M, Offermann G, Beige J. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J. 2008 Jan 8.

  60. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Reply-Cystatin C for Estimation of Residual GFR. Nephrol Dial Transplant. 2007 Dec 14.

  61. Timmers L, Thong SYM, Dekker FW, Boeschoten EW, Heijmans M, Rijken M, Weinman J, Kaptein AA, for the NECOSAD Study Group. Illness perceptions in dialysis patients and their association with quality of life. Psychology and Health 2008; 23: 679–690.

  62. Thong SYM, Kaptein AA, Benyamini Y, Krediet RT, Boeschoten EW, Dekker FW, for the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. Association between a self-rated health question and mortality in young and old dialysis patients: a cohort study. AJKD 2008; 52: 111-117.

  63. Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB. Mineral Metabolism and Mortality in Dialysis Patients: A Reassessment of the K/DOQI Guideline. Blood Purif 2008; 26: 231-237.

  64. de Mutsert R, Grootendorst DC, Boeschoten EW, Brandts H, van Manen JG, Krediet RT, Dekker FW; for the Netherlands Cooperative Study on the Adequacy of Dialysis-2 Study Group. Subjective global assessment of nutritional status is strongly associated with mortality in chronic dialysis patients. Am J Clin Nutr 2009: Epub ahead of print.

  Permanent link Permanent link  |  Print this page Print this page  |  E-mail this page E-mail this page